Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2007 Mar;117(3):568-75.

ECM remodeling in hypertensive heart disease.

Author information

1
Cardiovascular Research Institute and Department of Medicine, University of Rochester, Rochester, NY 14642, USA. bradford_berk@urmc.rochester.edu

Abstract

Hypertensive heart disease (HHD) occurs in patients that clinically have both diastolic and systolic heart failure and will soon become the most common cause of heart failure. Two key aspects of heart failure secondary to HHD are the relatively highly prevalent LV hypertrophy and cardiac fibrosis, caused by changes in the local and systemic neurohormonal environment. The fibrotic state is marked by changes in the balance between MMPs and their inhibitors, which alter the composition of the ECM. Importantly, the fibrotic ECM impairs cardiomyocyte function. Recent research suggests that therapies targeting the expression, synthesis, or activation of the enzymes responsible for ECM homeostasis might represent novel opportunities to modify the natural progression of HHD.

PMID:
17332884
PMCID:
PMC1804378
DOI:
10.1172/JCI31044
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center